Clinical trials: Bipolar Disorder Depression
Schizophrenia, Schizoaffective Disorder
Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
The purpose of this study is to get a better understanding of the side effect burden and identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified
- Trial name
- SATIETY (NCT01269710)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of North Carolina, Chapel Hill
Depression, Bipolar Disorder
Liothyronine (T3) for Bipolar Depression
This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.
- Trial name
- T3 (NCT00790738)
- Testing
- Liothyronine (T3)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health
Metabolic Syndrome, Bipolar Depression
Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance
The study is an open-label 8-week adjunctive trial of pioglitazone for the acute relief of bipolar depression comorbid with metabolic syndrome/insulin resistance.
- Conditions
- Metabolic Syndrome, Bipolar Depression, Insulin Resistance
- Trial name
- NCT00835120
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University Hospitals Cleveland Medical Center
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder, Insulin Resistance
Pioglitazone for the Treatment of Bipolar Depression
The primary objective is to test the hypothesis that adjunctive pioglitazone is more effective than placebo for the relief of acute depressive symptoms resulting from bipolar disorder.
- Trial name
- NCT01717040
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University Hospitals Cleveland Medical Center
Bipolar Disorder
NMDA Antagonists in Bipolar Depression
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression.
- Trial name
- NCT01833897
- Testing
- Standard of Care, Ketamine, D-cycloserine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder
Decision-Making in Bipolar Disorder
Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study.
- Trial name
- NCT01463111
- Testing
- Lithium, Valproate, Lamotrigine
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Emory University
Bipolar Disorder, Anxiety
Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
The primary objective is to test the hypothesis that Quetiapine XR (Extended Release) monotherapy and adjunctive therapy is effective in the acute treatment of bipolar depression and comorbid generalized anxiety disorder in…
- Conditions
- Bipolar Disorder, Anxiety, Anxiety Disorders, Substance Use Disorders
- Trial name
- NCT00671853
- Testing
- Quetiapine XR
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University Hospitals Cleveland Medical Center
Schizophrenia, Bipolar Disorder
Person-Centered Versus Measurement-Based Care in Mental Health
Fifteen minutes is the typical length of an outpatient medication management appointment for people with serious mental health conditions.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depression
- Trial name
- PCORI-SDM (NCT02507349)
- Testing
- Person-Centered Care, Measurement-Based Care
- Where
- 2 sites in United States
- Volunteers
- 2,443 people
- Sponsor
- University of Pittsburgh
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Mood Disorders, Bipolar Disorder
Technology Enhanced Family Treatment
The investigators propose to enhance the scalability of family-focused therapy (FFT), a 12-session evidence-based therapy for youth at high risk for mood disorders, through augmentation with a novel mobile phone application…
- Conditions
- Mood Disorders, Bipolar Disorder, Major Depression
- Trial name
- NCT03913013
- Testing
- Family-Focused Treatment with MCC App
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of California, Los Angeles
Depression, Bipolar Disorder
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder
The primary outcome of this study is to determine if predictors of response can select a population of patients with MDD that is effectively treatable by augmentation with ziprasidone.
- Trial name
- NCT01168674
- Testing
- ziprasidone, Sugar pill
- Volunteers
- 49 people
- Sponsor
- Tufts Medical Center
Bipolar Disorder, Depression
Implementing Health Plan-Level Care Management for Solo & Small Practices
This study will determine if a version of the chronic care model for individuals with mood disorders seen in small or solo practices can improve patient health.
- Trial name
- NCT02041962
- Testing
- Chronic Care Model for Mood Disorders, Educational Control
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- University of Michigan
Bipolar Depression
Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression
Lurasidone HCI is a compound that is a candidate for the treatment of bipolar I depression. This clinical study is designed to test the hypothesis that Lurasidone in combination with either Lithium or Divalproex is effective…
- Trial name
- PREVAIL3 (NCT01284517)
- Testing
- Lurasidone
- Where
- 75 sites in United States, Canada and 8 more
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Virtual Reality Job Interview Training in Severe Mental Illness
This is a randomized controlled trial to evaluate the community-based effectiveness of virtual reality job interview training (VR-JIT). Northwestern University is partnering with Thresholds Inc.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT03049813
- Testing
- Virtual Reality Job Interview Training, Supported Employment (Services as Usual)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Michigan
Bipolar Depression
An Open Label Trial of TMS Therapy for Bipolar Depression
Transcranial Magnetic Stimulation (TMS) is an increasingly accepted neurostimulation- based treatment for major depressive disorder.
- Trial name
- NCT02640950
- Testing
- NeuroStar TMS
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sheppard Pratt Health System
Bipolar Disorder, Depression, Bipolar
Lamotrigine for Symptoms of Geriatric Bipolar Depression
This is a 12-week, open label trial of lamotrigine for older adults (age 60 and older) with type I or type II Bipolar depression.
- Trial name
- Geri-BD SAD (NCT00621842)
- Testing
- Lamotrigine regular tablet formulation, Lamotrigine novel formulation
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- University Hospitals Cleveland Medical Center
Bipolar Disorder, Depression
A Trial of SAMe for Treatment-Resistant Bipolar Depression
S-adenosyl-L-methionine (SAMe) is a dietary supplement with antidepressant properties. SAMe's mechanism of action remains unclear, but it appears to be distinct from that of conventional antidepressants.
- Conditions
- Bipolar Disorder, Depression, Bipolar Depression
- Trial name
- NCT00762268
- Testing
- SAMe
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mclean Hospital
Bipolar Disorder I or II
Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
- Trial name
- NCT00259272
- Testing
- olanzapine
- Where
- 16 sites in France
- Volunteers
- 141 people
- Sponsor
- Eli Lilly and Company
Bipolar Disorder
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression
The FLAME Study is a 16-week clinical trial to study treatment with lamotrigine or fluoxetine in bipolar I, II and bipolar schizoaffective depressed adults.
- Trial name
- FLAME (NCT02389712)
- Testing
- Lamotrigine, Fluoxetine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic